These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35348191)

  • 1. Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells.
    Miyake K; Takano N; Kazama H; Kikuchi H; Hiramoto M; Tsukahara K; Miyazawa K
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35348191
    [No Abstract]   [Full Text] [Related]  

  • 2. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
    Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
    Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
    [No Abstract]   [Full Text] [Related]  

  • 3. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WEE1 kinase inhibitor MK-1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status.
    Al-Jamaei AH; de Visscher JGAM; Subramanyam VR; Forouzanfar T; Sminia P; Doulabi BZ; Helder MN
    Oral Dis; 2023 Oct; 29(7):2640-2649. PubMed ID: 35672254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
    Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
    Hattori K; Takano N; Kazama H; Moriya S; Miyake K; Hiramoto M; Tsukahara K; Miyazawa K
    Oncol Lett; 2021 Sep; 22(3):680. PubMed ID: 34345305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.
    Deneka AY; Einarson MB; Bennett J; Nikonova AS; Elmekawy M; Zhou Y; Lee JW; Burtness BA; Golemis EA
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe.
    Chen TM; Huang CM; Setiawan SA; Hsieh MS; Sheen CC; Yeh CT
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
    Chang I; Wang CY
    J Biol Chem; 2016 Aug; 291(35):18199-209. PubMed ID: 27369083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
    Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
    Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
    Ge H; Yao Y; Jiang Y; Wu X; Wang Y
    Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
    Mudianto T; Campbell KM; Webb J; Zolkind P; Skidmore ZL; Riley R; Barnell EK; Ozgenc I; Giri T; Dunn GP; Adkins DR; Griffith M; Egloff AM; Griffith OL; Uppaluri R
    Clin Cancer Res; 2021 Apr; 27(8):2326-2339. PubMed ID: 33547198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition.
    Diab A; Kao M; Kehrli K; Kim HY; Sidorova J; Mendez E
    Mol Cancer Res; 2019 May; 17(5):1115-1128. PubMed ID: 30679201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
    Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
    Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.